Hunton Andrews Kurth LLP represented NewTech Investment Holdings (“NewTech”) in a transaction with Orgenesis, Inc. pursuant to which NewTech entered into a convertible loan agreement with Orgenesis and received warrants representing the right to purchase shares of Orgenesis common stock.

Orgenesis, Inc. is a global biotech company working to unlock the potential of cell and gene therapies in an affordable and accessible format.

The Hunton Andrews Kurth deal team was led by Corporate partner Phil Haines and included assistance from counsel Adam Lyons and associates Kelli Rice, Lexi Williams, Kaitlyn Thorson and Neimann Gipson. Corporate partner Henry Harve assisted on matters related to the issuance of warrants, with Eric Markus and Marissa Rogers (beneficial ownership analysis) and Allison Mantor (tax).